NEW USES OF A MUTALIZED LACTONASE AND COMPOSITIONS
Patent Information
- Application Number
- DE602020077186
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-03-19
- Filing Date
- 2020-03-16
- Publication Date
- 2026-09-30
- Estimated Expiration
- 2040-03-16
AI Technical Summary
Existing technologies do not effectively enhance the sensitivity of bacteria to antimicrobial agents, leading to potential resistance development and high agent concentrations.
A mutated lactonase from the phosphotriesterase-like lactonase family, with a tryptophan substitution to isoleucine at position 263, increases bacterial sensitivity to antimicrobial agents, reducing the required agent concentration and preventing resistance.
The mutated lactonase enhances bacterial sensitivity by at least a factor of 2, allowing for reduced antimicrobial agent doses and preventing resistance development.
Description
[0001] This application describes new uses of a mutated lactonase and compositions containing it.
[0002] Some bacteria use a molecular communication system called Quorum Sensing (QS) to coordinate many biological functions such as virulence or biofilm formation. They notably use acyl-homoserine lactones (AHLs) as communication molecules.
[0003] The formation of bacterial biofilms leads to both medical and environmental problems. Therefore, it is important to find solutions to effectively eliminate bacterial biofilms.
[0004] The following documents are known: WO2014 / 167140, which describes, in particular, mutated hyperthermophilic phosphotriesterases, including the mutated phosphotriesterase W263I, with enhanced lactonase activity compared to a non-mutated hyperthermophilic phosphotriesterase, as well as compositions comprising a mutated phosphotriesterase and possibly an antibiotic; and WO2008 / 145865, which describes hyperthermophilic phosphotriesterases with a combination of mutations and their uses. However, these documents do not mention the combination of these mutated hyperthermophilic phosphotriesterases with antimicrobial agents to increase bacterial susceptibility to said antimicrobial agents.
[0005] Thus, the present invention relates to the use of a mutated lactonase belonging to the phosphotriesterase-like lactonase family to increase the sensitivity of bacteria to antimicrobial agents compared to the use of antimicrobial agents alone,in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine, and, said mutated lactonase having the sequence SEQ ID NO: 1 in which at least the amino acid tryptophan W at position 263 is substituted by the amino acid isoleucine I, and, said bacterial susceptibility to antimicrobial agents is increased by at least a factor of 2, said antimicrobial agent is used at a concentration of 10 µM to 100 mM, said mutated lactonase is used at a concentration of 0.1 mg / L to 10 g / L or at a concentration of 1 µg / cm² to 1 mg / cm², in which the antimicrobial agent is selected from the group consisting of antibiotics or a mixture of antibiotics, disinfectants or a mixture of disinfectants, biocides or a mixture of biocides and bacteriophages, whether naturally present in the environment or not, or a cocktail of such bacteriophages,and in which the use is chosen from among the prevention and / or treatment of plant infections, application to material contaminated by said bacteria or likely to be so contaminated, and use as a food supplement for humans or animals or as an animal feed product.
[0006] This mutated lactonase is derived from the hyperthermophilic lactonase of Sulfolobus solfataricus (SsoPox) or Saccharolobus solfataricus. The hyperthermophilic lactonase of Sulfolobus solfataricus (SsoPox) or Saccharolobus solfataricus exhibits both phosphotriesterase and lactonase activity. It belongs to the phosphotriesterase-like lactonase family.
[0007] The enzymes of the phosphotriesterase-like lactonase family have a conserved three-dimensional structure. Thus, according to the present invention, said mutated lactonase comprises at least the substitution of the amino acid tryptophan located at the beginning of loop 8 of the enzymes of the Phosphotriesterase-Like Lactonase family by the amino acid isoleucine.
[0008] According to this application, the mutated lactonase may include other mutations, in addition to the tryptophan mutation located at the beginning of loop 8 of the enzymes in the Phosphotriesterase-Like Lactonase family. These additional mutations may, for example, enhance the properties of the mutated lactonase or improve its stability.
[0009] This application describes in particular the use of a mutated lactonase belonging to the phosphotriesterase-like lactonase family to increase the sensitivity of bacteria to antimicrobial agents compared to the use of antimicrobial agents alone, in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine.
[0010] According to a particularly preferred embodiment, the mutated lactonase of the invention is derived from the hyperthermophilic lactonase of Sulfolobus solfataricus (SsoPox) having the sequence SEQ ID NO: 1 in which the amino acid tryptophan at position 263 is substituted by an Isoleucine I. Thus, in this embodiment, the mutated lactonase has the sequence SEQ ID NO: 2 and has a mutation at position 263 compared to the sequence SEQ ID NO: 1. SsoPox Wild-type SEQ ID NO: 1 SsoPox mutated W263I SEQ ID NO: 2
[0011] The tryptophan located at the beginning of loop 8 corresponds to the residue at position 263 of the primary structure. However, in the case of other enzymes of the phosphotriesterase-like lactonase family, it may be a different position in the primary structure, but it will always be the tryptophan residue located at the beginning of loop 8 of the enzymes of the Phosphotriesterase-Like Lactonase family.
[0012] In one embodiment, the mutated lactonase includes at least the substitution of tryptophan by isoleucine at position 263 of its sequence, as shown in the sequence SEQ ID NO: 2. Indeed, the mutated lactonase may include other mutations besides the one at position 263 of its sequence. These additional mutations may, for example, enhance the properties of the mutated lactonase with sequence SEQ ID NO: 2 or improve its stability.
[0013] Thus, when a given antimicrobial agent is used in combination with the mutated lactonase as defined above, and in particular with the mutated lactonase of sequence SEQ ID NO: 2, the sensitivity of bacteria to this antimicrobial agent is increased compared to the use of the same antimicrobial agent alone. This means that the amount of antimicrobial agent required to eliminate these bacteria or inhibit their growth can be reduced when the antimicrobial agent is used with the mutated lactonase as defined above, and in particular with the mutated lactonase of sequence SEQ ID NO: 2. Consequently, the toxicity associated with the use of potentially high concentrations of the antimicrobial agent is reduced. This also helps prevent the development of resistance mechanisms to antimicrobial agents in bacteria.
[0014] In order to measure the sensitivity of bacteria to antimicrobial agents, it is possible to measure, according to methods known to those skilled in the art: the Minimum Inhibition Concentration (MIC) the Minimum Biofilm Eradication Concentration (MBEC) the relative abundance of proteins involved in resistance to antimicrobial agents (efflux pumps, porins) the expression of genes of the CRISPR-Cas system involved in resistance to bacteriophages.
[0015] Thus, for a given dose of antimicrobial agent, the observation of a decrease in the minimum inhibition concentration, a decrease in the minimum biofilm eradication concentration, a variation in the relative abundance of proteins involved in resistance to antimicrobial agents, or an alteration in the expression of genes of the CRISPR-Cas system involved in resistance to bacteriophages means that the sensitivity of bacteria to antimicrobial agents is increased.
[0016] In one embodiment, the sensitivity of bacteria to antimicrobial agents is increased by at least a factor of 2 compared to the use of said antimicrobial agents alone.
[0017] This means that the sensitivity of bacteria to antimicrobial agents is increased by a factor of 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 compared to the use of said antimicrobial agents alone.
[0018] In a particularly preferred embodiment, the sensitivity of bacteria to antimicrobial agents is increased by a factor of 2 to 20 compared to the use of said antimicrobial agents alone.
[0019] The term " antimicrobial agent " refers to a compound that kills a microorganism or inhibits its growth.
[0020] In a particular embodiment, an antimicrobial agent may, for example, be an antibacterial agent, an antifungal agent, an antiviral agent, an antiprotozoal agent, an antiparasitic agent or a combination thereof.
[0021] An antimicrobial agent can, for example, be an inorganic compound, an organic compound, a protein, an antibody, a sugar, a nucleic acid, or a combination of these.
[0022] In a particular embodiment, the antimicrobial agent may be chosen from the group consisting of antibiotics or a mixture of antibiotics, disinfectants or a mixture of disinfectants, biocides or a mixture of biocides and bacteriophages possibly naturally present in the environment or not, or a cocktail of such bacteriophages.
[0023] Thus, in a particular embodiment, the antimicrobial agent is chosen from the group consisting of antibiotics or a mixture of antibiotics, disinfectants or a mixture of disinfectants, biocides or a mixture of biocides and bacteriophages possibly naturally present in the environment or not, or a cocktail of such bacteriophages.
[0024] By "we mean antibiotic ", any agent capable of killing a bacterium or reducing, limiting or inhibiting its growth.
[0025] Antibiotics can be bactericidal or bacteriostatic. This refers to... bactericidal antibiotics » , any agent capable of killing a bacterium. By " bacteriostatic antibiotics » , any agent capable of reducing, limiting or inhibiting bacterial growth, without killing the bacteria.
[0026] By "we mean disinfectant "A disinfectant is any substance applied to a non-living (inert) or living (such as skin) object that is capable of killing or inhibiting the growth of microorganisms present on the object. A disinfectant for personal use, that is, applied to external surfaces of the body, such as the skin, is called a " antiseptic » .
[0027] The term "biocide" refers to any substance or preparation intended to destroy, repel, or render harmless harmful organisms, to prevent the action of harmful organisms, or to control them, by chemical or biological means. In other words, biocides are substances that act on or against harmful organisms.
[0028] By "we mean bacteriophage ", any virus capable of infecting bacteria. Two types of bacteriophages can be distinguished: lytic phages infect the bacterium, hijack its cellular machinery to reproduce and destroy the cell to release new phages; lysogenic, or temperate, phages insert their DNA into that of the bacterium in the form of a prophage.
[0029] By "we mean bacteriophages possibly naturally present in the environment or not » ,bacteriophages naturally present in the environment as well as bacteriophages not present in the environment and added by a third party in order to eliminate bacteria.
[0030] Ledit antibiotique peut être choisi parmi le groupe consistant en : Amikacine, Amoxicilline, Amoxicilline / clavulanate, Ampicilline, Amprolium, Apramycine, Aspoxicilline, Aureomycine, Avilamycine, Azithromycine, Bacitracine, Bambermycine, Baquiloprime, Benzylpenicilline, Bicozamycine, Carbadox, Cefacetrile, Cefalexine, Cefalonium, Cefalotine, Cefapyrine, Cefazoline, Cefdinir, Cefquinome, Ceftiofur, Ceftriaxone, Cefuroxime, Chloramphenicol, Chlortetracycline, Ciprofloxacine, Clarithromycine, Clindamycine, Cloxacilline, Colistine, Dalbavancine, Danofloxacine, Decoquinate, Diclazuril, Dicloxacilline, Difloxacine, Doripenem, Doxycycline, Enramycine, Enrofloxacine, Ertapenem, Erythromycine, Florfenicol, Flumequine, Fosfomycine, Framycetine, acide fusidique, Gentamicine, Gentamicine Sulfate, Gramicidine, bromhydrate d'halofuginone, Hetacilline, Imipenem, Imipenem / cilastatine, Josamycine, Kanamycine, Kitasamycine, Laidlomycine, Lasalocide , Levofloxacine, Lincomycine,chlorhydrate de lincomycine, Maduramycine, Marbofloxacine, Mecillinam, Meropeneme, Miloxacine, Minocycline, Mirosamycine, Monensine, Moxifloxacine, Nafcilline, acide nalidixique, Narasine, Neomycine, Neomycine / oxytetracycline, Neosporine, Nicarbazine, Norfloxacine, Novobiocine, Ofloxacine, Orbifloxacine, Oritavancine, Oxacilline, acide oxolinique , Oxytetracycline, Paromomycine, hydroxyde de penethamate, Penicilline, Penicilline G Potassium, Penicilline procaine, Penicilline V potassium, Phenethicilline, Phenoxymethylpenicilline, Pirlimycine, Polymyxine, Polymyxine B, Polysporine (bacitracine / polymyxine), Pristinamycine, Rifampicine, Rifaximine, Roxarsone, Salinomycine, Semduramicine, Spectinomycine, Spiramycine, Streptomycine, Sulfachlorpyridazine, Sulfadiazine, Sulfadimerazine, Sulfadimethoxazole, Sulfadimethoxine, Sulfadimethoxine et ormetoprim 5:3, Sulfadimidine, Sulfadoxine, Sulfafurazole, Sulfaguanidine, Sulfamethazine, Sulfamethoxazole / trimethoprime, Sulfamethoxine,Sulfamethoxypyridazine, Sulfamonomethoxine, Sulfanilamide, Sulfaquinoxaline, Sulfasalazine, Sulfisoxazole, Surfactin, Telavancin, Terdecamycin, Tetracycline, Thiamphenicol, Tiamulin, Ticarcillin, Tilmicosin, Tobicillin, Tobramycin, Trimethoprim, Trimethoprim / Sulfonamide, Tulathromycin, Tylosin, Valnemulin, Vancomycin, Virginiamycin.,
[0031] The disinfectant said agent may include an alcohol, a chlorine, an aldehyde, an oxidizing agent, an iodine, an ozone, a phenolic compound, a quaternary ammonium compound or a mixture of two or more of these.
[0032] The disinfectant may include formaldehyde, orthophthalaldehyde, glutaraldehyde, silver dihydrogen citrate, polyaminopropyl biguanide, sodium bicarbonate, lactic acid, chlorine bleaching agent, methanol, ethanol, n-propanol, 1-propanol, 2-propanol, isopropanol, hypochlorite, chlorine dioxide, dichloroisocyanurate, monochloroisocyanurate, hydantoin, sodium hypochlorite, calcium hypochlorite, sodium dichloroisocyanurate, sodium chlorite, 4-methylbenzenesulfonamide, sodium salt, 2,4-dichlorobenzyl alcohol, performic acid, paracetic acid, potassium permanganate, potassium peroxymonosulfate, phenol, phenylphenol, chloroxylenol, hexachlorophene, thymol, amylmetacresol, benzalkonium chloride, cetyltrimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride,boric acid, brilliant green, chlorhexidine gluconate, providone-iodine, mercurochrome, manuka honey, octenidine dihydrochloride, polyhexamethylene biguanide, Peruvian balsam, hydrogen peroxide, organic peroxide, peroxyacid, organic hydroperoxide, peroxide salt, acid peroxides, and mixtures of two or more of these.
[0033] The said biocide may be chosen from the group consisting of: active biocidal peroxides such as hydrogen peroxide, mono- and polyfunctional alcohols, aldehydes, acids, ozone, naphtha compounds and compounds containing an alkali metal, a transition metal, a metal of group III or group IV, sulfur, nitrogen or a halogen atom and mixtures of two or more of these.
[0034] The said biocide is selected from the group consisting of: formaldehyde, glutaraldehyde, peracetic acid, alkali metal hypochlorites, quaternary ammonium compounds, 2-amino-2-methyl-1-propanol, cetyltrimethylammonium bromide, cetylpyridinium chloride, 2,4,4-trichloro-2-hydroxy diphenyl ether, 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea, zinc oxide, zinc ricinoleate, pentachlorophenol, copper naphthenate, tributyltin oxide, dichlorophene, p-nitrophenol, p-chloro-m-xylenol, beta-naphthol, 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, salicylanilide, bromoacetic acid, alkyl quaternary ammonium acetate, sodium ethylmercury thiosalicylate, orthophenylphenate sodium, n-alkyl (C2 to Cs) dimethyl benzyl ammonium chloride, organoborates, 2,2-(1-methyltrimethylene dioxy)-bis-(4-methyl-1,3,2-dioxaborinane), 2,2-oxybis(4,4,6-trimethyl)-1,3,2-dioxaborinane, ethylene glycol monomethyl ether, parahydroxybenzoates, organic boron compounds,8-Hydroxyquinoline, sodium pentachlorophenate, alkyl dimethyl ethyl benzyl ammonium chloride, alkylammonium salts, 1,3,5-triethylhexahydro-1,3,5-triazine, strontium chromate, halogenated phenols, 2-bromo-4-phenylphenol, silver salts such as silver nitrate, silver chloride, silver oxide and elemental silver, organic peroxides, silver sulfadiazine, sodium dichloro-S-triazinetrione, 4-chloro-2-cyclohexylphenol, 2-chloro-4-nitrophenol, paraffin substitute, 3-chloro-3-nitro-2-butanol, 2-chloro-2-nitro-1-butanol stearate, 2-chloro-2-nitrobutyl acetate, 4-chloro-4-nitro-3-hexanol, 1-chloro-1-nitro-1-propanol, 2-chloro-2-nitro-1-propanol, triethyltin chloride, 2,4,5-trichlorophenol, 2,4,6-trichlorophenol, 1,3-dichloro-5,5-dimethylhydantoin, tris(hydroxymethyl)nitromethane, nitroparaffins, 2-nitro-2-ethyl-1,3-propanediol, 2-ethyl-2-nitro-1,3-propanediol, 2-methyl-2-nitro-1,3-propanediol, hexahydro-1,3,5-tris(2-hydroxyethyl)-S-triazine,hexahydro-1,3,5-tris(tetrahydro-2-furanyl)-methyl-S-triazine, methylene bis(thiocyanate), 2,2-dibromo-3-nitrilopropionamide, beta-bromo-3-nitrostyrene, fluorinated compounds, N-ethyl-N-methyl-4-(trifluoromethyl)-2-(3,4-dimethoxyphenyl)benzamide, pentachlorophenol, dichlorophene, orthophenylphenol, dibicyclo(3,1,1 or 2,2,1)-heptyl polyamines, di-bicyclo-(3,1,1 or 2,2,1)-heptanyl polyamines and mixtures of two or more of these.
[0035] The bacteriophage in question may belong to the families of Myoviridae, Siphoviridae, Podoviridae, Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Plasmaviridae and Tectiviridae or a cocktail of the latter.
[0036] The type of antimicrobial agent to use depends on the type of bacteria to be eliminated.
[0037] The term " bacterium"Bacteria" refers to a genus of prokaryotic microorganisms scientifically classified as such. Most bacteria can be classified as Gram-positive or Gram-negative.
[0038] The bacteria can be chosen from among gram-positive and gram-negative bacteria.
[0039] THE " Gram-positive bacteria " are bacteria linked by a single lipid membrane and containing a thick layer of peptidoglycans (20 to 80 nm) which retains crystal violet staining in a Gram staining technique.
[0040] THE " Gram-negative bacteria " are bacteria linked by a cytoplasmic membrane as well as by an outer cell membrane, containing only a thin layer of peptidoglycans between the two membranes, which does not allow the crystal violet dye to be retained in a Gram staining technique.
[0041] Said bacteria may be chosen from the group consisting of: Acinetobacter baumannii, Aerococcus viridans, Aeromonas caviae, Aeromonas hydrophila, Aeromonas jandaei, Aeromonas salmonicida, Aeromonas sobria, Aeromonas veronii, Agrobacterium tumefaciens, Aliivibrio fischeri, Aliivibrio salmonicida, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Burkholderia cepacia complex, Burkholderia pseudomallei, Burhkolderia mallei, Chlamydia trachomatis, Chromobacterium violaceum, Clavibacter michiganensis, Clostridium botulinum, Clostridium difficile, Comamonas acidovorans, Comamonas testosteronii, Delftia acidovorans, Desulfovibrio desulfuricans, Desulfovibrio gigas, Desulfovibrio vulgaris, Dickeya dadanantii, Dickeya solanii, Edwarsiellosis anguillarum, Edwarsiellosis ictaluri, Edwarsiellosis piscicida, Edwarsiellosis tarda, Enterobacterium catenabacteriul, Enterococcus faecalis, Erwinia amylovora, Escherichia coli, Francisella noatunensis,Francisella tularensis, Gallionella ferruginea, Klebsiella pneumoniae, Lactococcus garvieae, Legionella pneumophila, Mycobacterium fortuitum, Mycobacterium marinum, Nocardia asteroids, Nocardia crassostreae, Nocardia seriolae, Pantoea agglomerans, Pantoea ananatis, Pantoea stewartii, Pectobacterium atrosepticum, Pectobacterium carotovorum, Porphyromonas gingivalis, Proteus mirabilis, Pseudomonas aeruginosa, Pseudomonas anguilliseptica, Pseudomonas fluorescens, Pseudomonas savastanoi, Pseudomonas syringae, Renibacterium salmoninarum, Salmonella enterica, Serratia liquefaciens, Serratia marcescens, Shewanella japonica, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus iniae, Streptococcus mutans, Streptomyces scabiei, Thiobacillus ferooxidans, Vibrio cholerae, Vibrio harveyi, Vibrio parahaemolyticus, Vibrio vulnificus, Xanthomonas campestris, Xanthomonas citri, Xanthomonas oryzae, Xanthomonas translucens, Xylella fastidiosa, Yersinia pestis,Yersinia ruckeri.,
[0042] Bacteria can be resistant to treatment with one or more antimicrobial agents alone.
[0043] Thus, in the case where bacteria are resistant to treatment with one or more given antimicrobial agents, one or more other antimicrobial agents are administered in association with the mutated lactonase as defined above and in particular with the mutated lactonase of sequence SEQ ID NO: 2. In this case, the use of the mutated lactonase as defined above and in particular with the mutated lactonase of sequence SEQ ID NO: 2 makes it possible to reduce the dose of antimicrobial agents necessary to eliminate these bacteria or inhibit their growth and therefore, to avoid the development of resistance mechanisms to these other antimicrobial agents by the bacteria.
[0044] The mutated lactonase of the invention is used at an effective dose.
[0045] The term "effective dose" refers to a sufficient dose of mutated lactonase to increase the sensitivity of bacteria to antimicrobial agents.
[0046] The effective dose of mutated lactonase depends on the nature of the antimicrobial agents used and the bacteria to be eliminated.
[0047] The mutated lactonase as defined above and in particular with the mutated lactonase of sequence SEQ ID NO: 2 can be used at a concentration of 0.1 mg / L to 10 g / L (liquid concentration) or of 1 µg / cm 2< to 1 mg / cm 2< (surface concentration in solid).
[0048] The mutated lactonase of the invention can be used at a concentration of 10 mg / L to 2 g / L. The mutated lactonase of the invention can be used at a concentration of 5 µg / cm² to 500 µg / cm².
[0049] The said antimicrobial agent is used at an effective dose.
[0050] By "we mean effective dosea sufficient dose of antimicrobial agents to kill said bacteria or inhibit their growth.
[0051] The effective dose of antimicrobial agents depends on the bacteria to be eliminated.
[0052] The said antimicrobial agent can be used at a concentration of 10 µM to 100 mM.
[0053] The said antimicrobial agent can be used at a concentration of 1 mM to 100 mM.
[0054] The effective dose of antimicrobial agents is reduced by at least a factor of 2 compared to the effective dose of said antimicrobial agents alone.
[0055] This means that the effective dose of antimicrobial agents is reduced by a factor of 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 compared to the effective dose of said antimicrobial agents alone.
[0056] The effective dose of antimicrobial agents is reduced by a factor of 2 to 20 compared to the effective dose of said antimicrobial agents alone.
[0057] In another aspect, the application describes the use of a mutated lactonase, as defined in the first aspect, to inhibit bacterial growth.
[0058] Thus, in this other aspect, and in a particular embodiment, the application describes the use of a mutated lactonase belonging to the phosphotriesterase-like lactonase family in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine and at least one antimicrobial agent to inhibit bacterial growth, in which the inhibition of bacterial growth is increased by at least a factor of 2 compared to the use of said antimicrobial agent alone.
[0059] In this other aspect, and in another particular embodiment, the application describes the use of a mutated lactonase and at least one antimicrobial agent to inhibit bacterial growth, said mutated lactonase having the sequence SEQ ID NO: 1 in which amino acid W at position 263 is substituted by the amino acid isoleucine I, in which the inhibition of bacterial growth is increased at least by a factor of 2 compared to the use of said at least one antimicrobial agent alone.
[0060] Bacterial growth refers to the increase in the number or mass of a given bacterium over a specific period. Bacterial growth can be measured using methods known to those skilled in the art.
[0061] We are talking about " bacterial inhibition"In the event of a halt or reduction in bacterial growth. We speak of inhibition of bacterial growth when bacterial growth has been reduced by at least 10% compared to normal growth conditions and up to 100%."
[0062] In a particular embodiment, said mutated lactonase has the sequence SEQ ID NO: 2.
[0063] Regarding the antimicrobial agent, the various embodiments detailed in the first aspect apply to this second aspect.
[0064] Similarly, according to this other aspect, the bacteria are as detailed in the different embodiments of the first aspect of the invention.
[0065] The mutated lactonase and at least one antimicrobial agent are used at an effective dose. In particular, the effective dose of the antimicrobial agent may be reduced by at least a factor of 2 compared to the effective dose of at least one antimicrobial agent alone.
[0066] In another aspect, the application describes the use of a mutated lactonase, as defined in the first aspect, to increase the sensitivity of bacteria to bacteriophages.
[0067] Thus, in this other aspect, and in a particular embodiment, the application describes the use of a mutated lactonase belonging to the phosphotriesterase-like lactonase family in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine and at least one bacteriophage to increase the sensitivity of bacteria to bacteriophages, possibly naturally present in the environment or not, compared to the use of said at least one bacteriophage alone.
[0068] In one particular embodiment, this other aspect describes the use of a mutated lactonase and at least one bacteriophage to increase the sensitivity of bacteria to bacteriophages, possibly naturally present in the environment or not, compared to the use of said at least one bacteriophage alone, said mutated lactonase having the sequence SEQ ID NO: 1 in which the amino acid W at position 263 is substituted by the amino acid isoleucine I.
[0069] Thus, in a particular embodiment, said mutated lactonase has the sequence SEQ ID NO: 2.
[0070] As with the first aspect of the invention, in one embodiment, the sensitivity of bacteria to bacteriophages is increased by at least a factor of 2 compared to the use of the bacteriophage alone.
[0071] Thus, when a given bacteriophage is used in combination with the mutated lactonase as defined above, and in particular with the mutated lactonase of sequence SEQ ID NO: 2, the sensitivity of bacteria to this bacteriophage is increased compared to the use of the same bacteriophage alone. This means that the amount of bacteriophage required to eliminate these bacteria or inhibit their growth can be reduced when the bacteriophage is used with the mutated lactonase as defined above, and in particular with the mutated lactonase of sequence SEQ ID NO: 2. This also helps prevent the development of resistance mechanisms to bacteriophages by bacteria.
[0072] In one embodiment of this other aspect, said bacteriophage may belong to the family of Myoviridae, Siphoviridae, Podoviridae, Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Plasmaviridae and Tectiviridae or a cocktail of the latter.
[0073] Similarly, according to this other aspect, the bacteria are as detailed in the different embodiments of the first aspect of the invention.
[0074] In one particular embodiment, bacteria can be resistant to treatment with a bacteriophage alone.
[0075] As with the first aspect, the mutated lactonase and bacteriophage are used at an effective dose. Specifically, the effective dose of bacteriophages used can be reduced by at least a factor of 2 compared to the effective dose of bacteriophage alone.
[0076] In another aspect, the application describes compositions comprising a mutated lactonase as defined in the first aspect.
[0077] Thus, in this other aspect, and in a particular embodiment, the application describes a composition comprising as an active ingredient a mutated lactonase belonging to the phosphotriesterase-like lactonase family in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine and at least one antimicrobial agent, the effective dose of antimicrobial agent in said composition being present in an amount at least 2 times lower than that of said at least one antimicrobial agent alone.
[0078] In this other aspect, and in a particular embodiment, the application also describes a composition comprising as an active ingredient a mutated lactonase and at least one antimicrobial agent, said mutated lactonase having the sequence SEQ ID NO: 1 in which amino acid W at position 263 is substituted by the amino acid isoleucine I, the effective dose of antimicrobial agent in said composition being present in an amount at least 2 times lower than that of said at least one antimicrobial agent alone.
[0079] Thus, in a particular embodiment, said mutated lactonase has the sequence SEQ ID NO: 2.
[0080] Thus, in a particular embodiment, the application describes a composition comprising as an active ingredient a mutated lactonase belonging to the phosphotriesterase-like lactonase family in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine, and at least one antimicrobial agent, and in particular said mutated lactonase having the sequence SEQ ID NO: 1 in which at least the amino acid W at position 263 is substituted by the amino acid isoleucine I, the effective dose of antimicrobial agent in said composition being present in an amount at least twice lower than that of said at least one antimicrobial agent alone.
[0081] Regarding the antimicrobial agent, the various embodiments detailed in the first aspect apply to this other aspect.
[0082] Similarly, according to this other aspect, the bacteria are as detailed in the different embodiments of the first aspect of the invention.
[0083] As with the first aspect, the mutated lactonase and the antimicrobial agent are used at an effective dose.
[0084] In this other aspect and according to one embodiment, said antimicrobial agent is used at a concentration of 10 µM to 100 mM.
[0085] In a particularly preferred embodiment, said antimicrobial agent is used at a concentration of 1 mM to 100 mM.
[0086] Thus, the application also describes a composition as defined above in which said antimicrobial agent is used at a concentration of 10 µM to 100 mM, preferably from 1 mM to 100 mM.
[0087] The mutated lactonase as defined above, and in particular the mutated lactonase with sequence SEQ ID NO: 2, can be used at a concentration of 0.1 mg / L to 10 g / L (liquid concentration) or from 1 µg / cm² to 1 mg / cm² (solid surface concentration). In a particularly preferred embodiment, the mutated lactonase as defined above, and in particular the mutated lactonase with sequence SEQ ID NO: 2, can be used at a concentration of 10 mg / L to 2 g / L.
[0088] In a particularly preferred embodiment, the mutated lactonase as defined above and in particular with the mutated lactonase of sequence SEQ ID NO: 2 can be used at a concentration of 5 µg / cm 2< to 500 µg / cm 2< .
[0089] Thus, the application also describes a composition as defined above in which said mutated lactonase is used at a concentration of 0.1 mg / L to 10 g / L, preferably from 10 mg / L to 2 g / L or at a concentration of 1µg / cm2< to 1 mg / cm2<, preferably from 5µg / cm2< to 500 µg / cm2<.
[0090] In a particular embodiment, the mutated lactonase as defined above can be applied to material contaminated by the said bacteria or likely to be contaminated.
[0091] In a particular embodiment, said material contaminated by said bacteria or likely to be contaminated may be selected from: medical devices such as dressings, catheters, endoscopes, implants, nebulizers, medical equipment, submerged surfaces such as boat hulls, port or oil infrastructure that can be the target of biofouling or biocorrosion, industrial installations such as cooling towers, air conditioning systems, bioreactors, piping, nebulizers, misting systems, basins.
[0092] In a particular embodiment, the mutated lactonase as defined above can be used as a plant protection product for the prevention and / or treatment of plant infections such as fire blight.
[0093] By " treatment ", we mean the means of treating a diagnosed pathology, the symptoms of which are visible. By " prevention ", we mean the means of preventing the said pathology from manifesting.
[0094] In a particular embodiment, said mutated lactonase as defined above may be used in a composition that may be formulated with at least one excipient suitable for its use in the form of a solution, oil, suspension, emulsion, nanoparticles, liposomes, granules or functionalized surface.
[0095] In another aspect, the application describes a method for the prevention and / or treatment of pathologies related to bacterial infections, including the administration of a mutated lactonase as defined in the first aspect and at least one antimicrobial agent.
[0096] Thus, in this other aspect and in a particular embodiment, the application describes a method for the prevention and / or treatment of pathologies related to bacterial infections, comprising the administration of a mutated lactonase belonging to the phosphotriesterase-like lactonase family in which at least the amino acid tryptophan located at the beginning of loop 8 is substituted by the amino acid isoleucine and at least one antimicrobial agent, the effective dose of antimicrobial agents in said composition being present in a quantity at least 2 times lower than that of said at least antimicrobial agent alone.
[0097] In this other aspect and in a particular embodiment, the application describes a method for the prevention and / or treatment of pathologies related to bacterial infections, comprising the administration of a mutated lactonase and at least one antimicrobial agent, said mutated lactonase having the sequence SEQ ID NO: 1 in which amino acid W at position 263 is substituted by the amino acid isoleucine I, the effective dose of antimicrobial agents in said composition being present in an amount at least 2 times lower than that of said at least one antimicrobial agent alone.
[0098] In one embodiment of this other aspect, said bacterial infections may be bacterial infections in plants such as fire blight.
[0099] In one embodiment of this other aspect, said bacterial infections may be bacterial infections in animals such as dysbiosis.
[0100] In one embodiment of this other aspect, said bacterial infections may be bacterial infections in humans such as pneumonia, nosocomial diseases, wounds, burns, eye infections, diabetic foot, for the treatment of dysbiosis, or for the treatment of dental plaque.
[0101] All the implementation methods of the different aspects described above are applicable to this other aspect.
[0102] The following figures and examples illustrate this application.
[0103] FIGURE 1 : Enumeration of P. aeruginosa bacteria recovered from biofilms formed in the presence or absence of SsoPox-W263I lactonase after treatment with H2O2 antiseptic.
[0104] Left: Enumeration of P. aeruginosa bacteria recovered from biofilms in the absence of treatment with the H2O2 antiseptic, in the absence of lactonase SsoPox-W2631 (Ctrl) or in the presence of lactonase SsoPox-W263I (SsoPox)
[0105] Right: Enumeration of P. aeruginosa bacteria recovered from biofilms after treatment with 10mM H2O2 antiseptic, in the absence of SsoPox-W263I lactonase (Ctrl) or in the presence of SsoPox-W263I lactonase (SsoPox)
[0106] FIGURE 2 : Increased sensitivity of Pseudomonas aeruginosa PA14 to the Intesti phage cocktail. The bars represent the number of bacteria after exposure to different concentrations of the phage cocktail (ranging from 0 to 50% (v / v)), treated with the mutated lactonase W263I (0.5 mg / mL) or with the inactive enzyme SsoPox-5A8 (0.5 mg / mL).
[0107] FIGURE 3: Modification of CRISPR-Cas system expression. The expression of the cas1, cas3, csy1, csy2, csy3 and csy4 genes of the CRISPR-Cas system was measured for the model strain of P. aeruginosa PA14 as well as for clinical isolates from diabetic foot infections (A11, B10, C5, C11, D10 and F3) and for the marine bacterium Chromobacterium violaceum CV12472. Cultures were treated with the enzyme SsoPox-W263I or the inactive enzyme SsoPox-5A8 (V27G / P67Q / L72C / Y97S / Y99A / T177D / R223L / L226Q / L228M / W263H). The histograms represent the expression of CRISPR-Cas system genes treated with SsoPox-W263I normalized to the values obtained with the inactive variant.
[0108] The error bars represent the variations for two technical duplicates of two biological replicates. *p-values < 0.05, **p-values < 0.01, ***p-values < 0.001 according to Student's t-test. ND indicates that the expression was not detected.
[0109] FIGURE 4Three-dimensional structure of enzymes in the phosphotriesterase-like lactonase family. The three-dimensional structure of enzymes in the phosphotriesterase-like lactonase family is conserved. The mutated tryptophan residue corresponds to the tryptophan located at the beginning of loop 8 of the enzymes in the phosphotriesterase-like lactonase family. In the case of the present invention, the mutated lactonase of SEQ ID NO: 2 (SsoPox W263I) has a mutated tryptophan residue located at the beginning of loop 8, corresponding to the tryptophan at position 263 of the primary structure.
[0110] FIGURE 5 : Enumeration of P. aeruginosa bacteria recovered from biofilms formed in the presence or absence of SsoPox-W263I lactonase after treatment with NaOCl bleach.
[0111] Left: Count of P. aeruginosa bacteria recovered from biofilms in the absence of NaOCl bleach treatment, in the presence of SsoPox-W2631 lactonase (solid bar) or an inactive variant of the SsoPox 5A8 enzyme (hatched bar).
[0112] Right: Enumeration of P. aeruginosa bacteria recovered from biofilms after treatment with 0.7mM NaOCl bleach, in the presence of SsoPox-W263I lactonase (solid bar) or an inactive variant of the SsoPox 5A8 enzyme (hatched bar).
[0113] A 2-log decrease is observed when bleach (0.7 mM) and lactonase SsoPox-W263I are used simultaneously, demonstrating the synergistic effect of the combination. Materials and Methods a) Sensitivity tests
[0114] The doses of antimicrobial agents required to eliminate bacterial biofilms are determined using the "MBEC (Minimal Biofilm Eradication Concentration) Assay TM" technique developed by Innovotech (Alberta, Canada) according to the supplier's data.
[0115] Bacterial biofilms are formed by bacterial growth in a medium and conditions adapted to the bacteria studied in the presence or absence of lactonase SsoPox-W263I of sequence SEQ ID NO: 2.
[0116] The bacteria are pre-cultured for 6 hours in oxygenated flasks under the conditions indicated in Table 1. MBEC plates are then inoculated by diluting the preculture 1 / 1000 with or without SsoPox-W263I lactonase at 0.5 mg / mL. After 24 hours of growth, the bacterial biofilms formed on the studs of the MBEC plate lid are rinsed by immersion for 5 minutes in a buffer solution (Table 1). The biofilms are then immersed in a buffer solution containing antimicrobial agents (disinfectants, bactericidal or bacteriostatic antibiotics, bacteriophages, biocides) for a duration representative of the mechanism of action of the antimicrobial agent being studied (1.5 hours for antiseptics, 3 hours for antibiotics, 4 hours for phages).After immersion in antimicrobial agents, the bacterial biofilms are rinsed for 5 minutes in a buffer solution and then incubated for 1 hour in a nutrient medium adapted to the bacteria studied and containing detergents to detach the biofilms (Table 1). After 1 hour of incubation, the bacteria detached from the biofilm and therefore present in the wells of the MBEC plate are serially diluted and spreads on suitable nutrient agar are carried out to perform bacterial counts and determine the number of bacteria that survived the combined treatment of the mutated enzyme SsoPox-W263I and the antimicrobial agent (. Figure 1 ). MBEC is the minimum concentration of antimicrobial agent to eradicate bacteria contained in the biofilm. Table 2: Experimental conditions for the determination of MBEC. LB (10 g / L peptone, 5 g / L extrait de levures, 10 g / L NaCl); tampon MOPS 10x (500 mM MOPS, 40 mM Tricine, 500 mM NaCl, 10 mM K2HSO4, 500 mM MgCl2, 100 mM CaCl2, 3 mM (NH4)6Mo7O24, 400 mM H3BO3, 30 mM Co(OAc)2, 10 mM CuSO4, 80 mM MnSO4, 10 mM ZnSO4 [pH 7.0], stérilisé par filtration 0,22 µm); milieu MOPS glutamate (MOPS 1x, 15 mM NH4Cl, 5 µM Fe2SO4, 4 mM K2HPO4, 25 mM glutamate); PBS (8 g / L NaCl, 0,2 g / L KCl, 1,44 g / L Na2HPO4, 0,24 g / L KH2PO4); Recovery LB (LB, 20 g / L saponine, 10 g / L Tween-80). Bacterium Strain Pre-culture conditions MBEC Nutrient Medium Temperature Hustle Buffer solution Recovery center Pseudomonas aeruginosa UCBPP-PA14 LB - 37°C MOPS glutamate 37°C Orbital - 110 RPM MOPS Recovery LB Chromobacterium violaceum ATCC-12472 LB - 37°C LB 25°C Orbital - 110 RPM PBS Recovery LB b) Expression of CRISPR-Cas system genes
[0117] The bacteria were cultured in MOPS medium for P. aeruginosa and LB medium for C. violaceum, in the presence of the mutated lactonase SsoPox-W263I (0.5 mg / ml) or its inactive variant 5A8 (0.5 mg / ml). After 16 hours of culture (stationary phase), the bacteria were recovered by centrifugation.
[0118] RNA was extracted and purified using the PureLink® RNA Mini Kit (ThermoFisher) according to the manufacturer's recommendations, then processed with the TURBO DNA-free™ Kit (ThermoFisher) to remove genomic DNA contamination. Sample quality was verified by 1.5% agarose gel electrophoresis, and the nucleic acid content was measured with a NanoDrop 2000 spectrophotometer (Thermo Scientific) at OD260 nm. Complementary DNA (cDNA) was synthesized using the TaqMan® Reverse Transcription Reagent Kit (ThermoFisher) according to the manufacturer's recommendations. RT-PCR was then performed using the LuminoCt® SYBR® Green qPCR ReadyMix™ Kit and a CFX thermocycler (Bio-Rad) with specific primer pairs.PCR amplification was performed using the following method: Denaturation for 5 minutes at 94°C, followed by 29 cycles of [1 minute at 94°C, 1 minute at 55°C, 30 seconds at 72°C] for amplification, and then a final elongation step for 7 minutes at 72°C. Fluorescence of the samples was measured at the end of each cycle, and the denaturation curves were analyzed using CFX Manager™ software (Bio-Rad). Gene expression was normalized by the expression of a 5S RNA housekeeping gene. Table 3: Primer sequences used to assess gene expression in the CRISPR-Cas system Bacterial species Target gene Sequence P. aeruginosa case1 Forward TCAAGGACTCGCTGATCCTG (SEQ ID NO:3) Reverse GATCATGAAGTCCAGGGCCT (SEQ ID NO:4) cas3 Forward GGTTGATCGTCAGCCATCAT (SEQ ID NO:5) Reverse GGCCTTTTCTTTTGCGTCT (SEQ ID NO:6) csy1 Forward TCTTCGAGCATGACTTCGGA (SEQ ID NO:7) Reverse TGGCGAGGTTGTTATGGACT (SEQ ID NO:8) csy2 Forward CGTCCGAAGAAGAAGCATCG (SEQ ID NO:9) Reverse CGCAGCGGTGTTTCTCTATC (SEQ ID NO:10) csy3 Forward AAGACCAAGGACCGTGACC (SEQ ID NO:11) Reverse AGCCCTGATCGTTCACGTAG (SEQ ID NO:12) csy4 Forward ACAGGATCGGCGTGAGCTT (SEQ ID NO:13) Reverse CCGCAACCCTTCCAGCCA (SEQ ID NO:14) 5S Forward GAACCACCTGATCCCTTCCC (SEQ ID NO:15) Reverse TAGGAGCTTGACGATGACCT (SEQ ID NO:16) C. violaceum cas1 Forward CAGGATGGCTGCGTCTTTG (SEQ ID NO:17) Reverse AACTACCTGGCCTACGGC (SEQ ID NO:18) cas3 Forward GGACAGGTAGGAGGCTTG (SEQ ID NO:19) Reverse TACGCGAGCAAGTGACCC (SEQ ID NO:20) csy1 Forward GGAATTCCGCCTCCGCCA (SEQ ID NO:21) Reverse GCCGACAGCGATGAAGAC (SEQ ID NO:22) csy2 Forward TCACCGGCCTGATGACGGC (SEQ ID NO:23) Reverse GAAGCGCTGGATGTAGTCG (SEQ ID NO:24) csy3 Forward GCGAGTACAGGCTTTCCAC (SEQ ID NO:25) Reverse AAACCATCTGGCGGCACTC (SEQ ID NO:26) csy4 Forward CGGAAGCATTGGCCGGTG (SEQ ID NO:27) Reverse CGCGCGACAGGCTGATG (SEQ ID NO:28) 5S Forward CTGGTGGCCATAGCGAGG (SEQ ID NO:29) Reverse GTCTGGCGGTGTCCTACTT (SEQ ID NO:30) Results a) Sensitivity tests
[0119] There Figure 1 This shows that without antiseptic treatment (left), the same number of bacteria are recovered from biofilms regardless of whether or not treatment with the mutated lactonase SsoPox-W263I has been administered. After treatment for 1 hour 30 minutes with 10 mM of the antiseptic H2O2, no bacteria are recovered from the biofilm with the use of mutated lactonase SsoPox-W263I, whereas 10⁴ to 10⁵ bacterial cells are recovered without lactonase. In the control sample (ctrl) prepared with an inactive variant of SsoPox-5A8 (V27G / P67Q / L72C / Y97S / Y99A / T177D / R223L / L226Q / L228M / W263H), 100 mM of antiseptic is required to completely eradicate the biofilm.
[0120] This means that using an antiseptic and a mutated SsoPox-W263I lactonase significantly reduces the number of bacteria recovered from the biofilm compared to using the antiseptic alone or the mutated SsoPox-W263I lactonase alone.
[0121] The results shown in Table 3 demonstrate that the presence of the mutated lactonase SsoPox-W263I reduces the required concentration of antibiotic and antiseptic (gentamicin, tobramycin, and H2O2) for eliminating P. aeruginosa biofilms by a factor of 10. The same trend, with a reduction factor of at least 20, is observed for a biofilm of the marine bacterium C. violaceum treated with a biocide used in antifouling paints for boat hulls.
[0122] The preventive use of the mutated lactonase SsoPox-W263I, in addition to the biocide, therefore makes it possible to significantly reduce the use of biocidal products which have a negative impact on the environment and which are known to facilitate the emergence of resistant bacteria in hospital or natural settings. Table 4 MBEC with or without use of the mutated lactonase SsoPox W263I : Bacterium Strain Type of biocide Name of the biocide SsoPox W263I MBEC Pseudomonas aeruginosa UCBPP-PA14 Antibiotic Gentamicin - 20 µg / mL 0.5 mg / mL 2 µg / mL Pseudomonas aeruginosa UCBPP-PA14 Antibiotic Tobramycin - 10 µg / mL 0.5 mg / mL 1 µg / mL Pseudomonas aeruginosa UCBPP-PA14 Antiseptic H2O2 - 100 mm 0.5 mg / mL 10 mm Chromobacterium violaceum ATCC-12472 Broad-spectrum biocide Preventol A4S (Dichlofluanid) - <200 µM 0.5 mg / mL >10 µM
[0123] In addition, Pseudomonas aeruginosa bacteria are also treated with the mutated lactonase W263I and a bacteriophage cocktail (Instesti cocktail; Microgen Russia) with satisfactory results.
[0124] The bacterium P. aeruginosa PA14 is treated with the mutated enzyme SsoPox-W2631 and the Intesti phage cocktail, or with the Intesti phage cocktail and the inactive variant SsoPox-5A8. The Intesti phage cocktail consists of a mixture of sterile phage filtrates directed against Shigella flexneri (serovariants 1, 2, 3, 4, 6), Shigella, Proteus vulgaris, Proteus mirabilis, Enterococcus, Staphylococcus, and Pseudomonas aeruginosa, and excipients such as 8-hydroxyquinoline sulfate monohydrate at 0.0001 g / ml (estimated content). It is marketed by Intesti-bacteriophage, Microgen, Russia. figure 2This shows that the bacterium P. aeruginosa PA14 treated with the mutated enzyme SsoPox-W263I and the Intesti phage cocktail is more sensitive to the Intesti phage cocktail than the bacterium treated with the inactive variant SsoPox-5A8 and the Intesti phage cocktail. Indeed, the bacterium treated with the inactive enzyme SsoPox-5A8 and the phage cocktail is minimally affected by the Intesti phage cocktail, while fewer bacteria are counted after treatment with the mutated enzyme SsoPox-W263I. b) Expression of CRISPR-Cas system genes
[0125] The CRISPR-Cas system is involved in bacterial defense against bacteriophages. To determine whether the mutated enzyme SsoPox-W263I affects the regulation of the CRISPR-Cas system, the expression levels of the cas1, cas3, csy1, csy2, csy3, and csy4 genes of the CRISPR-Cas system were measured in P. aeruginosa PA14 and clinical isolates of P. aeruginosa from diabetic foot infections (A11, B10, C5, C11, D10, F3), as well as in the marine strain of Chromobacterium violaceum CV12472. Primers targeting these different genes were created from the genomes of P. aeruginosa PA14 and C. violaceum CV12472 (Table 2). The cultures were treated with the enzyme SsoPox-W263 or the inactive enzyme SsoPox-5A8 (V27G / P67Q / L72C / Y97S / Y99A / T177D / R223L / L226Q / L228M / W263H).
[0126] Gene expression is completely abolished in P. aeruginosa PA14 after treatment with the mutated enzyme SsoPox-W263I. In B10 and C11, gene expression is decreased by a factor of 5.5 and 8, respectively. In A11 and D10, the expression of the csy1-4 genes is significantly reduced. Conversely, in F3, gene expression is increased by a factor of 1.7 on average. In C. violaceum, the expression of the cas3 and csy2-4 genes is significantly decreased. These results show that the SsoPox-W263I enzyme impacts the regulation of the CRISPR-Cas system. c) Demonstration of a synergistic effect between the mutated lactonase W263I and a biocide (NaOCl)
[0127] It is shown at the Figure 5that without treatment with sodium hypochlorite (NaOCl) (left), the same number of bacteria are recovered from biofilms whether or not there has been treatment with the mutated lactonase W263I. After treatment with 0.7 mM sodium hypochlorite and the mutated lactonase W263I, the number of bacteria recovered from biofilms was reduced by 2 Log compared to the use of sodium hypochlorite alone.
[0128] These results show that the use of sodium hypochlorite in association with the mutated lactonase W263I significantly reduces the number of bacteria recovered from the biofilm compared to the use of sodium hypochlorite alone or mutated lactonase W263I alone, thus showing the existence of a synergistic effect between sodium hypochlorite and mutated lactonase W263I.
Claims
1. Use of a mutated lactonase belonging to the phosphotriesterase-like lactonase family to increase the susceptibility of bacteria to antimicrobial agents compared to the use of antimicrobial agents alone, wherein at least the amino acid tryptophan at the beginning of loop 8 is substituted by the amino acid isoleucine, and, said mutated lactonase having the sequence SEQ ID NO: 1 wherein at least the amino acid tryptophan W at position 263 is substituted by the amino acid isoleucine I, and, said susceptibility of bacteria to antimicrobial agents is increased by at least a factor of 2, said antimicrobial agent is used at a concentration from10 µM to 100 mM, said mutated lactonase is used at a concentration from 0,1 mg / L to 10 g / L or at a concentration from 1µg / cm2 to 1 mg / cm2, wherein the antimicrobial agent is selected from the group consisting of antibiotics or a mixture of antibiotics, disinfectant agents or a mixture of disinfecting agents, biocides or a mixture of biocides and bacteriophages that may or may not be naturally present in the environment, or a cocktail of such bacteriophages, and wherein the use is chosen from - prevention and / or treatment of plant infections, - application to material contaminated or likely to be contaminated with said bacteria, and - use as a food supplement for humans or animals or as an animal nutrition product.
2. The use of a lactonase according to claim 1, wherein said antibiotic is selected from the group consisting of: Amikacin, Amoxicillin, Amoxicillin / clavulanate, Ampicillin, Amprolium, Apramycin, Aspoxicillin, Aureomycin, Avilamycin, Azithromycin, Bacitracin, Bambermycin, Baquiloprim, Benzylpenicillin, Bicozamycin, Carbadox, Cefacetrile, Cefalexin, Cefalonium, Cefalonium, Cefalotin, Cefapyrine, Cefazoline, Cefdinir, Cefquinoma, Ceftiofur, Ceftriaxone, Cefuroxime, Chloramphenicol, Chlortetracycline, Ciprofloxacin, Clarithromycin, Clindamycin, Cloxacillin, Colistin, Dalbavancin, Danofloxacin, Decoquinate, Diclazuril, Dicloxacillin, Difloxacin, Doripenem, Doxycycline, Enramycin, Enrofloxacin, Ertapenem, Erythromycin, Florfenicol, Flumequine, Fosfomycin, Framycetin, Fusidic Acid, Gentamicin, Gentamicin Sulfate, Gramicidin, Halofuginone Hydrobromide, Hetacillin, Imipenem, Imipenem / Cilastatin, Josamycin, Kanamycin, Kitasamycin, Laidlomycin, Lasalocid, Levofloxacin, Lincomycin, Lincomycin Hydrochloride, Maduramycin, Marbofloxacin, Mecillinam, Meropenem, Miloxacin, Minocycline, Mirosamycin, Monensin, Moxifloxacin, Nafcillin, Nalidixic Acid, Narasine, Neomycin, Neomycin / Oxytetracycline, Neosporine, Nicarbazine, Norfloxacin, Novobiocin, Ofloxacin, Orbifloxacin, Oritavancin, Oxacillin, Oxolinic Acid, Oxytetracycline, Paromomycin, Penethamate Hydroxide, Penicillin, Penicillin G Potassium, Penicillin Procaine, Penicillin V Potassium, Phenethicillin, Phenoxymethylpenicillin, Pirlimycin, Polymyxin, Polymyxin B, Polysporine (bacitracin / polymyxin), Pristinamycin, Rifampicin, Rifaximin, Roxarsone, Salinomycin, Semduramicin, Spectinomycin, Spiramycin, Streptomycin, Sulfachlorpyridazine, Sulfadiazine, Sulfadimerazine, Sulfadimethoxazole, Sulfadimethoxine, Sulfadimethoxine and Ormetoprim 5:3, Sulfadimidine, Sulfadoxine, Sulfafurazole, Sulfaguanidine, Sulfamethazine, Sulfamethoxazole / trimethoprim, Sulfamethoxin, Sulfamethoxypyridazine, Sulfamonomethoxin, Sulfanitramide, Sulfaquinoxaline, Sulfasalazine, Sulfaxazole, Surfactin, Telavancin, Terdecamycin, Tetracycline, Thiamphenicol, Tiamulin, Ticarcillin, Tilmicosin, Tobicillin, Tobramycin, Trimethoprim, Trimethoprim / Sulfonamide, Tulathromycin, Tylosin, Valnemuline, Vancomycin, Virginiamycin.
3. The use of a lactonase according to claim 1, wherein said disinfectant agent comprises an alcohol, chlorine, aldehyde, oxidizing agent, iodine, ozone, phenolic compound, quaternary ammonium compound or a mixture of two or more of these, preferably, said disinfectant agent includes formaldehyde, orthophthalaldehyde, glutaraldehyde, silver dihydrogen citrate, polyaminopropyl biguanide, sodium bicarbonate, lactic acid, chlorinated bleach, methanol, ethanol, n-propanol, 1-propanol, 2-propanol, isopropanol, hypochlorite, chlorine dioxide, di chloro isocyanurate, monochloro isocyanurate, hydantoin, sodium hypochlorite, calcium hypochlorite, sodium dichloro isocyanurate, sodium chlorite, 4-methylbenzenesulfonamide, sodium salt, 2,4-benzyl dichlorobenzyl alcohol, performic acid, paracetic acid, potassium permanganate, potassium peroxymonosulfate, phenol, phenylphenol, chloroxylenol, hexachlorophene, thymol, amylmetacresol, benzalkonuim chloride, cetyltrimethylammonium bromide, cetylpyridinium chloride, benzethonium chloride, boric acid, bright green, chlorhexidine gluconate, providone iodine, mercurochrome, manuka honey, octenidine dihydrochloride, polyhexamethylene biguanide, balsam of Peru, hydrogen peroxide, organic peroxide, peroxyacid, organic hydroperoxide, peroxide salt, acid peroxides, and mixtures of two or more of the these.
4. The use of a lactonase according to claim 1, wherein the biocide is selected from the group consisting of: active biocidal peroxides such as hydrogen peroxide, mono and polyfunctional alcohols, aldehydes, acids, ozone, naphtha compounds, and compounds containing an alkali metal, a transition metal, a group III or group IV metal, a sulphur, nitrogen or halogen atom and mixtures of two or more of these, preferably, said biocide is selected from the group consisting of: formaldehyde, glutaraldehyde, peracetic acid, alkali metal hypochlorites, quaternary ammonium compounds, 2-amino-2-methyl-1-propanol, cetyltrimethylammonium bromide, cetylpyridinium chloride, 2,4,4-trichloro-2-hydroxy diphenyl ether, 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea, zinc oxide, zinc ricinoleate, pentachlorophenol, copper naphthenate, tributyltin oxide, dichlorophene, p-nitrophenol, p-chloro-m-xylenol, beta-naphthol, 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, salicylanilide, bromoacetic acid, alkyl quaternary ammonium acetate, ethyl thiosalicylate sodium mercury, sodium orthophenylphenate, n-alkyl (C2 to Cs) dimethyl benzyl ammonium chloride, organoborates, 2,2-(1-methyltrimethylene dioxy)-bis-(4-methyl-1,3,2-dioxaborinan), 2,2-oxybis(4,4,6-trimethyl)-1,3,2-dioxaborinan, ethylene glycol monomethyl ether, parahydroxybenzoates, organic compounds of boron, 8-hydroxyquinoline, sodium pentachlorophenate, alkyl dimethyl ethyl benzyl ammonium chloride, alkylammonium salts, 1,3,5-triethylhexahydro-1,3,5-triazine, strontium chromate, halogenated phenols, 2-bromo-4-phenylphenol, silver salts such as silver nitrate, silver chloride, silver oxide and elemental silver, organic peroxides, silver sulfadiazine, sodium dichloro-S-triazinetrione, 4-chloro-2-cyclohexylphenol, 2-chloro-4-nitrophenol, paraffin substitute, 3-chloro-3-nitro-2-butanol, 2-chloro-2-nitro-1-butanol stearate, 2-chloro-2-nitrobutyl acetate, 4-chloro-4-nitro-3-hexanol, 1-chloro-1-nitro-1-propanol, 2-chloro-2-nitro-1-propanol, triethyltin chloride, 2,4,5-trichlorophenol, 2,4,6-trichlorophenol, 1,3-dichloro-5,5-dimethylhydantoin, tris(hydoxymethyl)nitromethane, nitroparaffins, 2-nitro-2-ethyl-1,3-propanediol, 2-ethyl-2-nitro-1,3-propanediol, 2- methyl-2-nitro-1,3-propanediol, hexahydro-1,3,5-tris(2-hydroxyethyl)-S-triazine, hexahydro-1,3,5-tris(tetrahydro-2-furanyl)-methyl-S-triazine, methylene bis(thiocyanate), 2,2-dibromo-3-nitrilopropionamide, beta-bromo-3-nitrostyrene, fluorinated compounds, N-ethyl-N-methyl-4-(trifluoromethyl)-2-(3,4-dimethoxyphenyl)benzamide, pentachlorophenol, dichlorophene, orthophenylphenol, di-bicyclo (3,1,1 or 2,2,1)-heptyl polyamines, di-bicyclo-(3,1,1 or 2,2,1)-heptanyl polyamines and mixtures of two or more of these.
5. The use of a lactonase according to claim 1, wherein the bacteriophage belongs to the family Myoviridae, Siphoviridae, Podoviridae, Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Plasmaviridae and Tectiviridae, or a cocktail thereof.
6. The use of a lactonase according to claim 1, wherein the effective dose of antimicrobial agent is decreased by at least a factor of 2 compared to the effective dose of antimicrobial agent alone.
7. The use of a lactonase according to claim 1, wherein the effective dose of an antimicrobial agent in said composition being present in an amount at least 2 times lower than that of said at least one antimicrobial agent alone.
8. The use of a lactonase according to claim 1, wherein said antimicrobial agent is used at a concentration from 1 mM to 100 mM.
9. The use of a lactonase according to claim 1, wherein said mutated lactonase is used at a concentration from 10 mg / L to 2 g / L or at a concentration from 5µg / cm2 to 500 µg / cm2.
10. Use of a lactonase according to claim 1, wherein the said material contaminated with said bacteria or likely to be contaminated is selected from: - medical devices such as dressings, catheters, endoscopes, implants, nebulizers - medical equipment - submerged surfaces such as boat hulls, port or oil infrastructure that may be the target of biofouling or biocorrosion, - industrial facilities such as air-cooled towers, air conditioning systems, bioreactors, piping, foggers, misters, ponds.
11. The use of a lactonase according to claim 1, wherein the prevention and / or treatment of plant infections is fire blight.
12. The use of a lactonase according to any one of claims 1 to 11, in a composition formulated with at least one excipient suitable for use under the form of a solution, of an oil, of a suspension, of an emulsion, of nanoparticles, of liposomes, of granules, or of functionalized surface.
